323 related articles for article (PubMed ID: 25280386)
21. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
[TBL] [Abstract][Full Text] [Related]
22. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
Mok T; Wu YL; Au JS; Zhou C; Zhang L; Perng RP; Park K
J Thorac Oncol; 2010 Oct; 5(10):1609-15. PubMed ID: 20808255
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.
Huang Y; Zhang L; Shi Y; Ma S; Liao M; Bai C; Zhang Q; Wang C; Luo F; Yu S; Qin S; Zhi X; Zhou C
Jpn J Clin Oncol; 2015 Jun; 45(6):569-75. PubMed ID: 25855621
[TBL] [Abstract][Full Text] [Related]
25. Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients.
Yamazaki N; Kiyohara Y; Kudoh S; Seki A; Fukuoka M
Int J Clin Oncol; 2016 Apr; 21(2):248-253. PubMed ID: 26499382
[TBL] [Abstract][Full Text] [Related]
26. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
28. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
29. From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.
Mazzoni F; Rotella V; Pratesi N; Boni L; Simi L; Orlando C; Comin CE; Maddau C; Di Costanzo F
Tumori; 2011; 97(2):160-5. PubMed ID: 21617709
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).
Yamada K; Takayama K; Kawakami S; Saruwatari K; Morinaga R; Harada T; Aragane N; Nagata S; Kishimoto J; Nakanishi Y; Ichinose Y
Jpn J Clin Oncol; 2013 Jun; 43(6):629-35. PubMed ID: 23599349
[TBL] [Abstract][Full Text] [Related]
31. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
[TBL] [Abstract][Full Text] [Related]
32. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
[TBL] [Abstract][Full Text] [Related]
33. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
34. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H; Fukuhara T; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Gemma A; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M
Lancet Oncol; 2019 May; 20(5):625-635. PubMed ID: 30975627
[TBL] [Abstract][Full Text] [Related]
35. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
[TBL] [Abstract][Full Text] [Related]
36. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
[TBL] [Abstract][Full Text] [Related]
37. Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.
Belani CP; Nemunaitis JJ; Chachoua A; Eisenberg PD; Raez LE; Cuevas JD; Mather CB; Benner RJ; Meech SJ
Cancer Biol Ther; 2013 Jul; 14(7):557-63. PubMed ID: 23792641
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.
Iyengar P; Kavanagh BD; Wardak Z; Smith I; Ahn C; Gerber DE; Dowell J; Hughes R; Abdulrahman R; Camidge DR; Gaspar LE; Doebele RC; Bunn PA; Choy H; Timmerman R
J Clin Oncol; 2014 Dec; 32(34):3824-30. PubMed ID: 25349291
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
Kubota K; Nishiwaki Y; Tamura T; Nakagawa K; Matsui K; Watanabe K; Hida T; Kawahara M; Katakami N; Takeda K; Yokoyama A; Noda K; Fukuoka M; Saijo N
J Thorac Oncol; 2008 Dec; 3(12):1439-45. PubMed ID: 19057270
[TBL] [Abstract][Full Text] [Related]
40. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
